Page last updated: 2024-12-09
2,5-dimercapto-1,3,4-thiadiazole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dimercaptothiadiazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 2723630 |
CHEMBL ID | 3185279 |
SCHEMBL ID | 12495049 |
SCHEMBL ID | 19435 |
MeSH ID | M0059235 |
Synonyms (74)
Synonym |
---|
bismuththiol |
1,3,4-thiadiazol-dithiol-(2,5) |
unii-2s78t9t08c |
2s78t9t08c , |
BB 0260229 |
1072-71-5 |
2,5-dimercapto-thiadiazole |
nsc-4645 |
dimercaptothiadiazole |
1,4-thiadiazolidine-2,5-dithione |
wln: t5nn dsj csh esh |
usaf a-8354 |
nsc4645 |
bismuthiol i |
2,5-dimercaptothiadiazole |
2,3,4-thiodiazole |
1,4-thiadiazole-2,5-dithiol |
usaf fa-4 |
usafa-8354 |
1,3,4-thiadiazolidine-2,5-dithione |
wln: t5nndsj csh esh |
STK367101 |
1,3,4-thiadiazole-2,5-dithiol, 98% |
ai3-18635 |
nsc 4645 |
2,5-dimercapto-1,3,4-thiodiazole |
einecs 214-014-1 |
py 61h |
1,3,4-thiadiazol-dithiol-(2,5) [german] |
2,5-dimercapto-1,3,4-thiadiazole , |
1,3,4-thiadiazole-2,5-dithiol |
bismuthiol |
D0622 |
B0593 |
AKOS000119872 |
A24678 |
1,3,4-thiadiazolidine-2,5-dithione;2,5-dimercapto-1,3,4-thiodiazole |
AKOS005485976 |
NCGC00248309-01 |
cas-1072-71-5 |
tox21_301157 |
dtxcid4020115 |
NCGC00255055-01 |
dtxsid6040115 , |
132120-63-9 |
5-sulfanyl-1,3,4-thiadiazole-2(3h)-thione |
STK560428 |
79509-46-9 |
FT-0610390 |
PS-4046 |
AM20080025 |
1,3,4- thiadiazole-2,5-dithiol |
SCHEMBL12495049 |
SCHEMBL19435 |
.delta.2-1,3,4-thiadiazoline-5-thione, 2-mercapto- |
2,5-dithiol-1,3,4-thiadiazole |
vanchem dmtd |
132120-64-0 |
bismuththiol i |
d 2 (chinese flotation agent) |
d 2 |
Q-200066 |
STR02271 |
CHEMBL3185279 |
mfcd00003103 |
AKOS028108714 |
F1995-0275 |
bismuthiol i, for spectrophotometric det. of bi, cu, pb, sb, >=99.0% |
1,3,4-thiadiazole-2-thione-5-thiol |
[1,3,4]thiadiazole-2,5-dithiol |
Q15632681 |
D88151 |
1,3,4-thiadiazole-2(3h)-thione, 5-mercapto- |
EN300-17339 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (7)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 11.2496 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 17.7214 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 54.9410 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 44.7070 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.2169 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 50.4772 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 7.9970 | 0.0006 | 27.2152 | 1,122.0200 | AID743219 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (11.76) | 18.7374 |
1990's | 1 (5.88) | 18.2507 |
2000's | 6 (35.29) | 29.6817 |
2010's | 7 (41.18) | 24.3611 |
2020's | 1 (5.88) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 31.48
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.48) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 1 (5.88%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (94.12%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |